Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement
CPT: Pharmacometrics & Systems Pharmacology · 2026-06 · 15 (6)
DOI: 10.1002/psp4.70275 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 31.05.2026. Verfasst von Todd Dumas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Certara USA, Radnor, Pennsylvania, USA. Hauptthemen laut MEDLINE: Immunoglobulin G, Immunoglobulins, Intravenous, Immunologic Deficiency Syndromes, Models, Biological. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
To support a post‐marketing requirement for pharmacokinetic (PK)‐focused assessments in patients ages 2–16 years, a model‐informed drug development approach was used to overcome enrollment barriers in recruiting pediatric subjects with primary immune deficiency (PID) disorders under Age 6 in a Phase 4 pediatric study. Models (1) characterized total immunoglobulin G (IgG) PK of Immune Globulin Intravenous [Human], 10% Liquid [IVIG] (BIVIGAM) in children and adolescents with PID; (2) quantified the impact of age and body weight; and (3) compared simulated exposure of IVIG between pediatric and adult subjects. Models were developed using pooled adult and pediatric data from 2 Phase 3/4 studies in 79 subjects (1243 IgG levels) with 3, 9, 13, and 54 subjects 2 to < 6 years, 6 to < 12 years, 12–16 years, and > 16 years, respectively. Serum IgG PK of IVIG following intravenous infusion was characterized using a 2‐compartment PK model with body weight on total IgG clearance and volumes of distribution. Model‐based clearance values when estimating allometric exponents were comparable across age‐group categories. Simulations predicted trough IgG levels for a virtual population of subjects for recommended IVIG 10% dosages of 300–800 mg/kg. Fixed and estimated allometric scaling allowed conservative extrapolation with simulations showing ≥ 90% of subjects would achieve trough levels ≥ 5 g/L (minimum recommended level) for a mid‐range dose of 500 mg/kg. Modeling and simulation were integral in confirming achievement of clinically acceptable trough IgG levels (~7 g/L) to support supplemental PK, efficacy, and dosing recommendations for patients ≥ 2 years of age. Trail Registration: NCT00538915 and NCT03164967
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara USA, Radnor, Pennsylvania, USA.
- ADMA Biologics, Inc, Boca Raton, Florida, USA.
- IMMUNOe Research, Centennial, Colorado, USA.
Zitieren
APA
Dumas, T., Mehr, S., Avila, R., Doman, A., Kestenberg, K., & Melamed, I. (2026). Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement. CPT: Pharmacometrics & Systems Pharmacology, 15(6). https://doi.org/10.1002/psp4.70275
Vancouver
Dumas T, Mehr S, Avila R, Doman A, Kestenberg K, Melamed I. Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(6). doi:10.1002/psp4.70275
BibTeX
@article{Dumas2026,
author = {Dumas, Todd and Mehr, Shahram and Avila, Rebecca and Doman, Amy and Kestenberg, Kaitlin and Melamed, Isaac},
title = {Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G Replacement},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/psp4.70275}
}
EUVIMED